We therefore hypothesized that treatment of DMD MuSCs with the PTPN1/2 inhibitor K884 would enhance their myogenic differentiation by activating JAK2/STAT3-mediated myogenic commitment and differentiation pathways. The gene discussed is STAT3; the disease is Duchenne muscular dystrophy.